Increasing trend of utilising active surveillance for Gleason Score 7 (3 + 4) prostate cancer-Reference-Cited by-同舟云学术

Increasing trend of utilising active surveillance for Gleason Score 7 (3 + 4) prostate cancer

Published:2023-08-31 Issue:6 Volume:132 Page:638-640
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU International

Author:

Bernardino Rui¹²^ORCID,Sayyid Rashid K.¹^ORCID,Leão Ricardo³^ORCID,Zlotta Alexandre R.¹,van der Kwast Theodorus⁴,Klotz Laurence⁵^ORCID,Fleshner Neil E.¹

Affiliation:

1. Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre University of Toronto Toronto Ontario Canada

2. Computational and Experimental Biology Group, NOVA Medical School, Faculdade de Ciências Médicas Universidade NOVA de Lisboa Lisbon Portugal

3. Hospitais Cuf Coimbra Portugal

4. Department of Laboratory Medicine and Pathobiology University of Toronto Toronto Ontario Canada

5. Division of Urology, Sunnybrook Health Sciences Centre University of Toronto Toronto Ontario Canada

Publisher

Wiley

Subject

Urology

Reference5 articles.

1. The CAPRA-S score

2. Diagnostic Accuracy of Prostate Biopsy for Detecting Cribriform Gleason Pattern 4 Carcinoma and Intraductal Carcinoma in Paired Radical Prostatectomy Specimens: Implications for Active Surveillance

3. Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative

4. Recommendations of Active Surveillance for Intermediate-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists

5. Serum and urinary biomarkers for detection and active surveillance of prostate cancer

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transcript Markers from Urinary Extracellular Vesicles for Predicting Risk Reclassification of Prostate Cancer Patients on Active Surveillance;Cancers;2024-07-04

2. Using active surveillance for Gleason 7 (3+4) prostate cancer: A narrative review;Canadian Urological Association Journal;2023-12-21